Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

AstraZeneca Wants to Build its Portfolio of Generic Drugs in China

publication date: Jan 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca plans to expand its branded generics business in China through M&A with China pharmas. At the same time, it will also promote its patent-protected drugs in the PRC, according to the company. This week, the British drugmaker began construction on its new $230 million manufacturing facility in Taizhou’s China Medical City, a project that was announced in October 2011. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors